Duloxetine HCl,Dosages,Treatment, Formulations,Drugs Descriptions,Consumer Information,Contraindications,Precautions, Diagnosis,Side Effects,Drug Reaction,Prevention,Supplement,Consumer Information,Pharmaceutical Development &Technology,Fda Approval,Uses,Vaccine Exporters,Material,Information of Diseases,Importers,Active Pharmaceutical Ingredients,Prevention, Exporters,Adverse Drug Suppliers, Raw Material Exporter, Formulation,Export,Drug Manufacturer,FDA Inspection,Emergency,Causes,Importer, Doxazosin Mesylate,Taj Pharmaceuticals Ltd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

Duloxetine HCl

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Duloxetine HCl Manufacturers in India Suppliers Duloxetine HCl Dossage Exporters Distributors Duloxetine HCl api active pharmaceuticals ingredients Duloxetine HCl manufacturers Side Effects bulk drugs raw material Dossage Duloxetine HCl companies Side Effects Dossage Importers Duloxetine HCl Dossage Duloxetine HCl Exporters Duloxetine HCl exporters Dossage FDA Dossage Duloxetine HCl Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Duloxetine Hydrochloride manufacturing pharmaceutical drugs pharmaceutical intermediates Duloxetine Hydrochloride pharmaceutical chemicals pharmaceutical raw materials Duloxetine Hydrochloride active pharmaceutical ingredients Duloxetine Hydrochloride committee active pharmaceutical ingredients manufacturer Duloxetine Hydrochloride Active Pharmaceutical Ingredients manufacturer Duloxetine Hydrochloride exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Duloxetine HCl, Duloxetine HCl manufacturer India, Duloxetine HCl product, Duloxetine HCl products, Api preparation, Certificate of Analysis API manufacturer product, Duloxetine HCl anti ulcer product, Certificate of Origin COA Duloxetine HCl COS Duloxetine HCl, pharmaceutical generic, pharmaceutical drug, medical, Duloxetine HCl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Duloxetine HCl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Duloxetine HCl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Duloxetine HCl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Duloxetine HCl ingredients, api, HIV Duloxetine HCl, tablets, capsules, syrup & protein Duloxetine HCl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Duloxetine HCl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Duloxetine HCl WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API
	Pharmaceuticals API List >>
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

capsule

HOME >> Pharmaceuticals API List 1 >> Duloxetine Hcl >> Dosage

DOSAGE
Duloxetine HCl CAS number 136434-34-9

Diabetic Peripheral Neuropathic Pain
Adults

PO 60 mg once daily without regard to meals.
Fibromyalgia
Adults

PO Start with 30 mg once daily for 1 wk. The dose may be increased to 60 mg once daily after 1 wk.
Generalized Anxiety Disorder
Adults

PO Start with 30 or 60 mg once daily without regard to meals. If the starting dosage is 30 mg once daily, the dosage may be increased to 60 mg once daily after 1 wk. Additional dosage increases should be in increments of 30 mg once daily (max, 120 mg once daily). There is no evidence that doses of more than 60 mg once daily confer additional benefit.
Major Depressive Disorder
Adults

PO 40 mg daily (given as 20 mg twice daily) to 60 mg daily (given once daily or as 30 mg twice daily) without regard to meals.
General Advice

* Advise patient to swallow capsule whole and not to crush, chew, or open capsule.
* Assess patients with major depressive disorders periodically to determine the need for maintenance treatment and appropriateness of dose.
* Efficacy of duloxetine in the treatment of generalized anxiety disorder beyond 10 wk has not been studied. Periodically evaluate patients for long-term usefulness of the drug.
* Efficacy of duloxetine in the management of diabetic peripheral neuropathic pain has not been evaluated beyond 12 wk.
* Efficacy of duloxetine in the management of fibromyalgia has not been evaluated beyond 3 months.

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE >>

SIDE EFFECTS

PRECAUTIONS

INTERACTION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj pharmaceuticals API Logo

More Api at Taj Pharmaceuticals Ltd.

Alfuzosin	Oseltamivir Phosphate	Amlodipine Besylate	Aripiprazole	Atorvastatin Calcium	Candesartan Cilaxetil	Cefdinir	Cetirizine Dihydrochloride	Ciprofloxacin HCl	Dextromethorphan Base	Diltiazem HCl
Domperidone Base	Domperidone Maleate	Doxazosin Mesylate	Duloxetine HCl	Dutasteride	Enalapril Maleate	Esomeprazole Magnesium	Famotidine	Fexofenadine HCl	Fluconazole	Fluoxetine HCl
Galantamine HBr	Ibuprofen	Caffeine

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.